Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.8136-8136
Hauptverfasser: Cairo, Mitchell S, Gallagher, Jack R, Barnes, Yvonne, Drea, Edward, Carroll, Susan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 8136
container_issue Supplement 1
container_start_page 8136
container_title Blood
container_volume 140
creator Cairo, Mitchell S
Gallagher, Jack R
Barnes, Yvonne
Drea, Edward
Carroll, Susan
description
doi_str_mv 10.1182/blood-2022-169864
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_169864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122051898</els_id><sourcerecordid>S0006497122051898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1374-b4d183b756e55e28648e420e2af6fe6d70fd742834a7e25498f2add320a834b63</originalsourceid><addsrcrecordid>eNp9kc1qGzEUhUVpoW7SB-juLluIUkmj-TFdGdM0AScNsbseNNIVUZmRBkkOzPv1wSLXXXd14XDO_fsI-cTZNeed-DqMIRgqmBCUN-uukW_Iiteio4wJ9pasGGMNleuWvycfUvrNGJeVqFfkz43KanTZYQIbwwSH4xQi7JbkEuwXb4qG8Pmw238BZTNG2Pjs6O0yYzxGp3FyGu6DD_kZo5oXoPCgsgtejeMCTzhHTOhzkV7wCh5jmNEnlxfY6xAR7lXWz2iuijPHkGbUJyPs89EssA3TrKJLwUOw8KTScJqoEoLyBjbjGOYi-DBekndWjQk__qsX5NfN98P2lu5-_rjbbnZU86qVdJCGd9XQ1g3WNYrypA6lYCiUbSw2pmXWtFJ0lVQtilquOyuUMZVgqmhDU10Qfu6ry64pou3n6CYVl56z_oSh_4uhP2HozxhK5ts5g2WxF4exT9qh12hcLNf2Jrj_pF8BtvWVEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Cairo, Mitchell S ; Gallagher, Jack R ; Barnes, Yvonne ; Drea, Edward ; Carroll, Susan</creator><creatorcontrib>Cairo, Mitchell S ; Gallagher, Jack R ; Barnes, Yvonne ; Drea, Edward ; Carroll, Susan</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-169864</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.8136-8136</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cairo, Mitchell S</creatorcontrib><creatorcontrib>Gallagher, Jack R</creatorcontrib><creatorcontrib>Barnes, Yvonne</creatorcontrib><creatorcontrib>Drea, Edward</creatorcontrib><creatorcontrib>Carroll, Susan</creatorcontrib><title>Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1qGzEUhUVpoW7SB-juLluIUkmj-TFdGdM0AScNsbseNNIVUZmRBkkOzPv1wSLXXXd14XDO_fsI-cTZNeed-DqMIRgqmBCUN-uukW_Iiteio4wJ9pasGGMNleuWvycfUvrNGJeVqFfkz43KanTZYQIbwwSH4xQi7JbkEuwXb4qG8Pmw238BZTNG2Pjs6O0yYzxGp3FyGu6DD_kZo5oXoPCgsgtejeMCTzhHTOhzkV7wCh5jmNEnlxfY6xAR7lXWz2iuijPHkGbUJyPs89EssA3TrKJLwUOw8KTScJqoEoLyBjbjGOYi-DBekndWjQk__qsX5NfN98P2lu5-_rjbbnZU86qVdJCGd9XQ1g3WNYrypA6lYCiUbSw2pmXWtFJ0lVQtilquOyuUMZVgqmhDU10Qfu6ry64pou3n6CYVl56z_oSh_4uhP2HozxhK5ts5g2WxF4exT9qh12hcLNf2Jrj_pF8BtvWVEQ</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Cairo, Mitchell S</creator><creator>Gallagher, Jack R</creator><creator>Barnes, Yvonne</creator><creator>Drea, Edward</creator><creator>Carroll, Susan</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol</title><author>Cairo, Mitchell S ; Gallagher, Jack R ; Barnes, Yvonne ; Drea, Edward ; Carroll, Susan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1374-b4d183b756e55e28648e420e2af6fe6d70fd742834a7e25498f2add320a834b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cairo, Mitchell S</creatorcontrib><creatorcontrib>Gallagher, Jack R</creatorcontrib><creatorcontrib>Barnes, Yvonne</creatorcontrib><creatorcontrib>Drea, Edward</creatorcontrib><creatorcontrib>Carroll, Susan</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cairo, Mitchell S</au><au>Gallagher, Jack R</au><au>Barnes, Yvonne</au><au>Drea, Edward</au><au>Carroll, Susan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>8136</spage><epage>8136</epage><pages>8136-8136</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-169864</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.8136-8136
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_169864
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T16%3A54%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatalities%20from%20Tumor%20Lysis%20Syndrome%20(TLS)%20after%20Anti-Hyperuricemic%20Monotherapy%20-%20Nationally%20Representative,%20Propensity%20Score%20Matched,%20Retrospective%20Study%20Comparison%20of%20Rasburicase%20and%20Allopurinol&rft.jtitle=Blood&rft.au=Cairo,%20Mitchell%20S&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=8136&rft.epage=8136&rft.pages=8136-8136&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-169864&rft_dat=%3Celsevier_cross%3ES0006497122051898%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122051898&rfr_iscdi=true